Mount Vernon Hospital
Welcome,         Profile    Billing    Logout  
 24 Trials 
35 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hoskin, Peter J
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
POPS, NCT02978014: A Trial Assessing Post-Operative Use of ProSpare, a Rectal Obturator in Prostate Cancer Radiotherapy

Recruiting
2
245
Europe
ProSpare, Rectal obturator
Royal Marsden NHS Foundation Trust, Institute of Cancer Research, United Kingdom
Cancer
12/24
12/24
Ardeshna, Kirit
CRUK-2004-001621-16, NCT00112931 / 2004-001621-16: Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Checkmark P3 data
Jun 2011 - Jun 2011: P3 data
Checkmark P3 data
Dec 2010 - Dec 2010: P3 data
Completed
3
462
Europe, RoW
rituximab, No treatment
University College, London, Cancer Research UK, Roche Pharma AG
Lymphoma
03/14
09/23
Nathan, Paul
ATOM, NCT06246149: Adjuvant Tebentafusp in High Risk Ocular Melanoma

Not yet recruiting
3
290
NA
Tebentafusp
European Organisation for Research and Treatment of Cancer - EORTC, Northwell Health Cancer Institute
Uveal Melanoma
11/32
11/32
NCT03223753: Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

Active, not recruiting
3
384
Canada, US
Educational Intervention, Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational, Internet-Based Intervention, Laboratory Biomarker Analysis, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Children's Oncology Group, National Cancer Institute (NCI)
Carcinoma In Situ, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
03/25
03/25
ARST2031, NCT04994132: A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Recruiting
3
118
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Dactinomycin, Actinomycin A IV, Actinomycin C1, Actinomycin D, Actinomycin I1, Actinomycin IV, Actinomycin X 1, Actinomycin-[thr-val-pro-sar-meval], Cosmegen, DACT, Dactinomycine, Lyovac Cosmegen, Meractinomycin, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate, Vinorelbine Tartrate, Biovelbin, Eunades, KW-2307, Navelbine, Navelbine Ditartrate, NVB, Vinorelbine Ditartrate, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
Children's Oncology Group, National Cancer Institute (NCI)
Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Metastatic Embryonal Rhabdomyosarcoma, Metastatic Rhabdomyosarcoma, Solid Alveolar Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma
09/27
09/27
NCT05529316: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Suspended
2
220
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034
Agenus Inc.
Advanced Melanoma
05/28
05/28
TebeMRD, NCT05315258: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Recruiting
2
850
Europe
Tebentafusp, IMCgp100
University of Oxford, Immunocore Ltd, Natera, Inc.
Melanoma (Skin), Melanoma, Uveal
06/25
06/26
NCT00082745: Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

Recruiting
N/A
3885
Europe, Canada, US, RoW
Laboratory Biomarker Analysis, Questionnaire Administration
Children's Oncology Group, National Cancer Institute (NCI)
Childhood Malignant Neoplasm
12/04
 
PRIMM, NCT03643289: Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics

Recruiting
N/A
450
Europe
East and North Hertfordshire NHS Trust, King's College London
Melanoma (Skin)
05/23
05/23
NCT03632343: The Pain Squad+ Smartphone App To Support Real-Time Pain Management for Adolescents With Cancer

Recruiting
N/A
222
Canada
Pain Squad+ with Nurse Support, Pain Squad+
The Hospital for Sick Children
Therapy-Associated Cancer
09/24
12/24
NCT05832138: ONLOOP Trial: Evaluating a New Surveillance and Support System for Survivors of Childhood Cancer in Ontario

Not yet recruiting
N/A
900
NA
ONLOOP program
The Hospital for Sick Children, Women's College Hospital, Ottawa Hospital Research Institute
Survivorship, Cancer, Heart Diseases, Secondary Cancer, Colorectal Cancer, Breast Cancer
05/25
06/26
NCT01120353: Childhood Cancer Survivor Study

Recruiting
N/A
50000
Canada, US
St. Jude Children's Research Hospital, National Cancer Institute (NCI), Fred Hutchinson Cancer Center, Nationwide Children's Hospital, M.D. Anderson Cancer Center, University of Southern California, Children's Hospital Medical Center, Cincinnati, University of California, San Francisco
Cancer
11/26
11/26
Lambert, Jonathan
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Calendar Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Exclusivity expiry in US
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
Grønberg, Bjørn H
TRIPLEX, NCT05223647: Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer

Recruiting
3
302
Europe, RoW
Thoracic radiotherapy, Chemo-immunotherapy, carboplatin/etoposide/durvalumab
Norwegian University of Science and Technology, St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, Alesund Hospital, Helse Stavanger HF, Oslo University Hospital, Helse Nord-Trøndelag HF, Helse Fonna, Drammen sykehus, University Hospital, Akershus, Erasmus Medical Center, Sahlgrenska University Hospital, Sweden, Karolinska University Hospital, Gävle Hospital, Sykehuset Innlandet HF, North Estonia Medical Centre, Nordlandssykehuset HF, Landspitali University Hospital, Lund University Hospital, University Hospital, Linkoeping
Small-cell Lung Cancer
01/26
10/29
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
ASTEROID, NCT03446547: Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)

Recruiting
2
106
Europe
Durvalumab, Medi4736
Vastra Gotaland Region, AstraZeneca
NSCLC, Stage I
07/24
07/24
DART, NCT04392505 / 2019-002537-11: Durvalumab(MEDI4736) After chemoRadioTherapy() for NSCLC-a Translational and Biomarker Study

Active, not recruiting
2
100
Europe
Durvalumab Injection, Imfinzi
Oslo University Hospital, AstraZeneca
Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage III, NSCLC, NSCLC, Stage III
05/25
05/33
NCT02041845: Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer

Active, not recruiting
N/A
177
Europe
45 Gy in 30 fractions, 60 Gy in 40 fractions
Norwegian University of Science and Technology, St. Olavs Hospital, Oslo University Hospital, University Hospital of North Norway, Sorlandet Hospital HF
Small Cell Lung Carcinoma
07/20
12/33
Walshe, Janice
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Harrison, Mark
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
Hall, Marcia
CORINTH, NCT04046133: Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of Anus

Recruiting
1b
50
Europe
Pembrolizumab, Radiotherapy, Chemotherapy (Mytomycin or Mitomycin and Capecitabine)
Cardiff University
Anal Cancer Stage III A, Anal Cancer Stage III B
11/22
11/22
VALTIVE1, NCT04523116: Validation of Tie2 as the First Tumour Vascular Response Biomarker for VEGF Inhibitors:

Recruiting
N/A
176
Europe
University of Manchester, Cancer Research UK, Centre for Trials Research, Cardiff University
Ovary Cancer
05/23
06/23
BriTROC-2, NCT05537844: Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma

Recruiting
N/A
250
Europe
Liz-Anne Lewsley, Ovarian Cancer Action
Ovarian Cancer, High Grade Serous Carcinoma, Carcinosarcoma, Ovarian, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, BRCA1 Mutation, BRCA2 Mutation
10/24
04/25
Polychronis, Andreas
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
300
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, Belrestotug, EOS884448, GSK4428859A, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
01/25
01/28
PROPHETIC, NCT04056247: Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Recruiting
N/A
2000
Europe, US, RoW
Plasma sample collection
OncoHost Ltd.
Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma
10/29
10/29
Serwatowski, Piotr
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT03917381 / 2018-003402-63: GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active, not recruiting
1/2
429
Europe, US, RoW
Acasunlimab, GEN1046, DuoBody®-PD-L1x4-1BB, Acasunlimab in combination with docetaxel (in a single expansion cohort), Acasunlimab in combination with pembrolizumab (in a separate expansion cohort), Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Genmab, BioNTech SE
Solid Tumors, Non-small Cell Lung Cancer, Urothelial Carcinoma, Endometrial Carcinoma, Triple Negative Breast Cancer, Squamous Cell Carcinoma of the Head and Neck, Cervical Cancer
01/25
10/25
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Checkmark Presentation of Trident -1 data for the treatment of NSCLC in AACR-NCI-EORTC 2021
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
Sutherland, Stephanie
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting
2/3
780
Europe
Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin
Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK
Breast Cancer
06/24
06/34
Ananthi, Balasubramanian
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Aamelfot, Christina
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29

Download Options